Newsbenzinga
Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders
· Published
Article summary
CapVest-backed Curium agrees to acquire Lantheus for up to $8B, expanding its global footprint in nuclear medicine.
An excerpt from the original article.
Comments —
Loading comments…